Cholinergic regulation of dopaminergic inputs into the striatum is critical for normal basal ganglia (BG) function. This regulation of BG function is thought to be primarily mediated by acetylcholine released from cholinergic interneurons (ChIs) acting locally in the striatum. We now report a combination of pharmacological, electrophysiological, optogenetic, chemogenetic, and functional magnetic resonance imaging studies suggesting extra-striatal cholinergic projections from the pedunculopontine nucleus to the substantia nigra pars reticulata (SNr) act on muscarinic acetylcholine receptor subtype 4 (M 4 ) to oppose cAMP-dependent dopamine receptor subtype 1 (D 1 ) signaling in presynaptic terminals of direct pathway striatal spiny projections neurons. This induces a tonic inhibition of transmission at direct pathway synapses and D 1 -mediated activation of motor activity. These studies provide important new insights into the unique role of M 4 in regulating BG function and challenge the prevailing hypothesis of the centrality of striatal ChIs in opposing dopamine regulation of BG output.
INTRODUCTION
The striatum is the primary gateway to the basal ganglia (BG) motor circuit and plays a critical role in regulating motor function, motivation, habit formation, and cognition (Albin et al., 1989; Alexander et al., 1990; Graybiel, 2008; Pisani et al., 2005) . Dopaminergic inputs to the striatum from the substantia nigra pars compacta (SNc) play an important role in regulating striatal output and BG-influenced behaviors (Beaulieu and Gainetdinov, 2011) . In addition, dopamine (DA) signaling in the striatum is dysregulated in multiple movement disorders and psychiatric illnesses (Albin et al., 1989; Goodchild et al., 2013; Wichmann and DeLong, 1996) .
A major regulator of DA signaling in the BG is acetylcholine (ACh), acting through muscarinic acetylcholine receptors (mAChRs) and nicotinic acetylcholine receptors (nAChRs) (Bonsi et al., 2011; Picciotto et al., 2012) . nAChRs are non-selective cation channels that have profound effects on DA release (Cachope and Cheer, 2014) and have been implicated in multiple disorders in which DA is disturbed (Crunelle et al., 2010) . mAChRs are G protein-coupled receptors that also modulate DA release and signaling (Kruse et al., 2014; Shin et al., 2015; Zhang et al., 2002) . For instance, mAChR agonists inhibit DA release and suppress behavioral effects of psychostimulants that act by increasing DA levels (Bendor et al., 2010; Foster et al., 2014 Foster et al., , 2016 Starke et al., 1989) . Furthermore, disturbances of mAChR signaling have been implicated in many neurologic and neuropsychiatric disorders that are thought to involve changes in DA signaling (Aosaki et al., 2010; Holt et al., 1999; Kataoka et al., 2010; Pisani et al., 2007) .
Cholinergic interneurons (ChIs) in the striatum are large, aspiny, tonically active interneurons that are thought to be central to the ability of ACh to modulate the BG (Holt et al., 1999; Pisani et al., 2007; Tanimura et al., 2017) . However, recent studies suggest that non-striatal sources of ACh may also regulate BG output. Hindbrain cholinergic nuclei of the pedunculopontine nucleus (PPN) and laterodorsal tegmental nucleus (LDT) project to BG nuclei and brain regions that regulate the BG such as the SNc (Dautan et al., 2014; Saper and Loewy, 1982) . Optogenetic or electrical activation of projections from either the PPN or LDT can modulate locomotion, reward, and gait (Wen et al., 2015; Xiao et al., 2016) , suggesting that cholinergic neurons in the hindbrain may also regulate BG output. However, the sites of action of these hindbrain cholinergic nuclei and the AChR subtypes they modulate are not well understood.
In recent years, M 4 has emerged as the primary mAChR subtype responsible for regulating DA signaling in the striatum (Conn et al., 2009) , as psychomotor effects of non-selective mAChR agonists are diminished in M 4 knockout (KO) mice (Gomeza et al., 2001; Guo et al., 2010) . Additionally, selective positive allosteric modulators (PAMs) of M 4 decrease amphetamine-induced increases in extracellular DA in the striatum and functional magnetic resonance imaging (fMRI) studies reveal that M 4 PAMs induce a profound reduction in amphetamine-induced activation of the striatum and other forebrain regions . Furthermore, M 4 PAMs reduce effects of DA-releasing stimulants on locomotor activity and other behavioral responses (Brady et al., 2008; Byun et al., 2014; Dencker et al., 2012; Foster et al., 2016) . Recent studies also suggest that M 4 PAMs act, in part, by inhibition of DA release in the striatum by release of an endocannabinoid from spiny projection neurons (SPNs) and activation of presynaptic cannabinoid receptor 2 (CB 2 ) on DA terminals (Foster et al., 2016) .
While the behavioral effects of M 4 PAMs are likely to be partially mediated by inhibition of DA release, M 4 is highly expressed in SPNs that express the DA receptor subtype 1 (D 1 ), form the direct pathway (D 1 -SPNs), and send inhibitory projections to the substantia nigra pars reticulata (SNr) (Hersch et al., 1994; Levey et al., 1991) . Activation of D 1 -SPNs in the striatum leads to GABA release, inhibition of GABAergic SNr projection neurons, and disinhibition of the thalamus, leading to excitation of the cortex and facilitating goal-directed movement. Interestingly, D 1 activates a unique G protein in D 1 -SPNs, Ga olf , that couples D 1 to activation of adenylyl cyclase (AC), formation of cAMP, and activation of protein kinase A (Corvol et al., 2007; Hervé , 2011; Zhuang et al., 2000) . This signaling pathway is critical for many of the behavioral actions of amphetamine that are reversed by M 4 PAMs (Drago et al., 1998; Zhuang et al., 2000) . The M 4 receptor couples to Ga i , which inhibits AC and can counteract the effects of D 1 /Ga olf activation (Onali and Olianas, 2002) , raising the possibility that M 4 PAMs may also directly inhibit D 1 signaling in D 1 -SPNs by inhibition of cAMP formation. Here, we report that M 4 PAMs reverse increases in locomotor activity induced by a D 1 agonist, which cannot be mediated by inhibition of DA release. Furthermore, pharmacological, genetic, molecular, and cellular studies reveal that this response is mediated by inhibition of D 1 signaling in D 1 -SPNs through opposing actions on AC. Surprisingly, the primary action of M 4 PAMs on D 1 signaling is not in the striatum, but on GABAergic terminals of D 1 -SPNs in the SNr. This finding challenges the traditional view that cholinergic regulation of BG function is mediated exclusively through ACh released from ChIs, and highlights an important role for extrastriatal sources of ACh projecting to other BG nuclei, which may also play a critical role in cholinergic regulation of DA signaling and activity through the BG motor circuit (Aosaki et al., 1995; Bolam et al., 1984; Bonsi et al., 2011; Hersch et al., 1994; Wilson et al., 1990) .
RESULTS

D 1 Agonists Induce Hyperlocomotion, Which Is
Reversed by M 4 PAM Administration Previously, we reported that the M 4 PAM VU0467154 reversed hyperlocomotion induced by amphetamine, a stimulant that acts by increasing extracellular DA. These studies also provided evidence that this effect is partially mediated by inhibition of DA release in the striatum Foster et al., 2016) . To determine whether the M 4 PAM can have actions that are independent of DA release, we studied the effect of VU0467154 on hyperlocomotion induced by the D 1 -selective agonist SKF82958. Consistent with previous reports, SKF82958 (1 mg/kg, intraperitoneal [i.p.] To further assess the mechanism by which M 4 PAMs may reduce responses to the D 1 agonist, we used a previously characterized mouse in which M 4 receptors are selectively deleted from D 1 -expressing neurons (Jeon et al., 2010) . These D 1 -M 4 KO mice display a hyperlocomotor response to SKF82958 (1 mg/kg, i.p.) that is similar to that of WT animals. However, VU0467154 (3-30 mg/kg, i.p., 10% Tween 80) failed to reduce the response to SKF82958 in D 1 -M 4 KO mice ( Figures 1C, 1D , and S1B; one-way ANOVA with Tukey's post hoc test, p > 0.05).
In order to determine whether the M 4 PAM has actions on motor function without administration of a D 1 agonist, we administered VU0467154 (3-30 mg/kg, i.p) to WT mice 30 min prior to testing. Animals administered VU0467154 showed significantly decreased spontaneous locomotion compared to vehicle controls (Figures S1C and S1D; one-way ANOVA with Tukey's post hoc test, p < 0.05). This suggests that M 4 activity may regulate direct pathway activity in baseline states, and raises the possibility that there is behaviorally relevant tonic inhibition of D 1 -SPNs by M 4 .
M 4 Receptors Co-localize with D 1 -SPN Terminals in the SNr Previous studies revealed a diverse expression pattern of M 4 throughout the brain, with particularly robust expression in the striatum, cortex, and the hippocampus (Levey et al., 1991) . In the striatum, M 4 is found on glutamatergic terminals, ChIs, and D 1 -SPNs (Levey et al., 1991; Hersch et al., 1994) . In addition, M 4 activation can inhibit D 1 /cAMP-mediated responses in the striatum (Jeon et al., 2010; Sá nchez-Lemus and Arias-Montañ o, 2006) , suggesting inhibition of D 1 signaling at the level of the striatum could contribute to the ability of M 4 PAMs to inhibit behavioral responses to the D 1 agonist. However, direct site infusion of D 1 modulators into the SNr provides intriguing evidence that activation of D 1 on D 1 -SPN terminals in the SNr also contributes to the effects of D 1 activation on locomotor activity (Trevitt et al., 2001 (Trevitt et al., , 2002 . To study the expression patterns of M 4 , we utilized a reporter mouse that expresses the red fluorescent protein td-Tomato in D 1 -SPNs combined with previously characterized antibodies (Hersch et al., 1994; Levey et al., 1991) . Similar to previous reports, M 4 puncta (green) can be seen in td-Tomatopositive cell bodies, suggesting likely M 4 expression on D 1 -SPNs ( Figure S2 ). Diffuse M 4 puncta were also observed throughout the striatum that sometimes co-localize with tdTomato, suggesting that M 4 is present on the dendrites of D 1 -SPNs as well as other neuropil, likely cortico-striatal projections ( Figure S2 ). In the striatum, M 4 staining was largely absent in an M 4 KO animal ( Figure S2 ). In the SNr, robust M 4 staining was observed in td-Tomato-positive puncta, suggesting that M 4 is robustly co-expressed with a marker for D 1 -SPN terminals ( Figure S2 ). We could not determine whether the M 4 staining on cell bodies in the SNr was specific for M 4 , as equally intense staining was observed only in the cell bodies of M 4 KO animals. However, loss of staining associated with D 1 terminals in M 4 KO suggests that M 4 is localized in terminal regions of D 1 -SPNs.
Cholinergic Fibers in the SNr Originate from the Hindbrain Cholinergic Nuclei To determine the source of ACh in the SNr, we utilized retrobeads that, when injected into a brain region, are retrogradely transported back to the soma of cells that project to that brain region (Katz et al., 1984) . We performed focal injections of these beads into the SNr ( Figure S3A ). When staining for cholinergic cells using VAChT antibody and a coronal sectioning technique, we could distinguish the LDT from the PPN ( Figure S3B ). In line with previous reports (Beninato and Spencer, 1987) , robust bead uptake can be seen in cholinergic cells of the PPN, but not the LDT, suggesting that the PPN is the main source of ACh in the SNr ( Figure S3C ). Additionally, when staining for VAChT in the SNr, cholinergic fibers can be visualized and their density estimated at a modest density of $6 fibers/100 mm 2 ( Figure S3D ). Figure S1 . Data are mean ± SEM with n = 8-12 per treatment group. *p < 0.05, **p < 0.01, ***p < 0.001; NS, not statistically significant by one-way ANOVA followed by Tukey's post hoc test. the cells and through membrane properties ( Figure S4A ). Bath application of 10 mM SKF82958 caused a leftward shift in cumulative probability of release with an $40% increase in mIPSC frequency (Figures 2A-2C ; Table S1 ; Wilcoxon signed-rank test, p < 0.05) without changes in mIPSC amplitude (Table S1 ; Wilcoxon signed-rank test, p > 0.05). Additionally, we confirmed that these responses are mediated by GABA A with bath application of 50 mM of the GABA A antagonist bicuculline, which abolished detectable events ( Figure S4B ). Taken together, these results confirm previous reports that D 1 activation robustly increases GABA release probability from D 1 -SPN terminals onto SNr neurons (Radnikow and Misgeld, 1998; Trevitt et al., 2002) .
Pre-treatment with the muscarinic agonist oxotremorine-M (Oxo-M; 10 mM) completely eliminated the effect of SKF82958 on mIPSCs. The M 4 -selective PAM VU0467154 (10 mM) mimicked the effect of Oxo-M (Table S1 ; Figures 2A-2C; oneway ANOVA with Tukey's post hoc test, p < 0.05). Lower concentrations of VU0467154 (5 mM) or Oxo-M (2 mM) failed to reduce the effects of 10 mM SKF82958 (Table S1 ; Figures S3C, S3D , and 2A-2C; one-way ANOVA with Tukey's post hoc test, p > 0.05). However, when combined, 5 mM VU0467154 and 2 mM Oxo-M significantly blocked the effects of 10 mM SKF82958 (Table S1 ; Figures 2A-2C; one-way ANOVA with Tukey's post hoc test, p < 0.05). This ability of a low concentration of VU0467154 to potentiate the response to a threshold concentration of Oxo-M is consistent with the M 4 PAM mechanism. These findings were confirmed in slices warmed to 30 C ( Figure S4F ).
In addition to evaluating effects of VU0467154 on the response to an exogenous agonist, we also performed studies in slices with channelrhodopsin 2 (ChR2) selectively expressed in choline acetyltransferase (ChAT)-positive cholinergic neurons to evoke ACh release. Optical stimulation of cholinergic afferents using 10 Hz, 5 ms, 470 nm light pulses reduced baseline mIPSC frequency by$20%, which is similar in magnitude to the effect of 10 mM Oxo-M ( Figure S4E ). At this intensity, optical stimulation alone did not inhibit the mIPSCs when stimulated with SKF82958 (Table S1 ; Figures 2D-2F; one-way ANOVA with Tukey's post hoc test, p > 0.05), providing an appropriate optical stimulation intensity for evaluation of the effects of the M 4 PAM. However, when combined with a concentration of VU0467154 (5 mM) that had no effect in the absence of optical stimulation, this intensity induced a robust inhibition of the effects of SKF82958 on mIPSC frequency (Table S1 ; Figures 2D-2F; one-way ANOVA with Tukey's post hoc test, p < 0.01). These data suggest that that ACh released in the SNr inhibits mIPSCs from D 1 -SPNs in the SNr and that the effect of activation of cholinergic afferents is potentiated by selective M 4 PAMs.
Genetic Deletion of M 4 in D 1 -SPNs Blocks Pharmacological Inhibition of D 1 -Mediated Responses
To test the hypothesis that M 4 expressed in D 1 -SPNs is responsible for the inhibition of D 1 -induced increases in GABA release probability, we performed identical studies in slices from D 1 -M 4 KO mice. Bath application of 10 mM SKF82958 significantly increased mIPSC frequency compared to baseline (Table  S1 ; Figures 3A-3C; Wilcoxon signed-rank test, p < 0.01). However, D 1 -mediated increases in mIPSC frequency were not blocked by 10 mM Oxo-M, 10 mM VU0467154, or a combination of subthreshold concentrations of VU0467154 (5 mM) and Oxo-M (2 mM) (Table S1 ; Figures 3A-3C; one-way ANOVA with Tukey's post hoc test, p > 0.05) in D 1 -M 4 KO mice. Again, neither SKF82958 nor the muscarinic agents altered mIPSC amplitude (Table S1 ; Wilcoxon signed-rank test, p > 0.05), and all events were blocked with 50 mM bicuculline ( Figure S4G ). Control studies were performed in which we found that bath application of 10 mM baclofen, a GABA B agonist, induced a similar decrease in mIPSC frequency in slices from WT and D 1 -M 4 KO animals (Figures S4H-S4J ; two-way t test, p > 0.05). These data suggest that the D 1 -SPN terminals in D 1 -M 4 KO mice were not altered in a homeostatic manner, and that mIPSCs could be inhibited by activation of another G protein-coupled receptor (Borgkvist et al., 2015) .
Importantly, D 1 -M 4 KO mice may bear deletions of M 4 from any neurons that express both M 4 and the D 1 receptor. Thus, it is conceivable that deletion of M 4 in other cells within the SNr in D 1 -M 4 KO mice could contribute to the loss of responses to M 4 activation in these mice. To control for this, we performed additional studies to confirm that the response to mAChR agonists and M 4 PAMs in the SNr could be rescued by restoring M 4 signaling in striatal neurons of D 1 -SPN KO mice by stereotaxic injection of a viral construct encoding the hM 4 Di designer receptor exclusively activated by a designer drug (DREADD) into the striatum (Krashes et al., 2011) . This DREADD is a modified M 4 receptor that no longer binds ACh, but can be selectively activated by clozapine-N-oxide (CNO), an inactive metabolite of clozapine. Bath application of 10 mM CNO to slices from animals expressing the hM 4 Di DREADD induced a robust inhibition of SKF82958-induced increases in mIPSC frequency (Table S1 ; Figures 3A-3C; one-way ANOVA with Tukey's post hoc test, p < 0.05). Additionally, application of 10 mM CNO alone produced a profound decrease in mIPSC frequency, suggesting that replacing M 4 with an M 4 DREADD to restore M 4 -dependent signaling is sufficient to decrease D 1 -SPN activity (Table S1 ; Figures 3A-3C; Wilcoxon signed-rank test, p < 0.05). Taken together, these studies suggest that selective activation of M 4 inhibits D 1 -induced increases in transmission at striato-nigral synapses by actions in D 1 -SPN terminals.
M 4 May Tonically Inhibit mIPSCs in D 1 -SPNs VU0467154 is a prototypical M 4 PAM that does not induce significant activation of M 4 by itself, but acts by potentiating the response to ACh . Thus, the finding that VU0467154 alone inhibits mIPSCs raises the possibility that ACh exerts a tonic inhibition of mIPSC frequency that is potentiated by the M 4 PAM. Consistent with this, there was an approximate doubling of mIPSC frequency from $4 Hz to $8 Hz in D 1 -M 4 KO mice relative to D 1 -Cre and WT mice (Table S1 ; Figures 4A and 4B ; one-way ANOVA with Tukey's post hoc test, p < 0.001). Furthermore, bath application of the non-subtypeselective mAChR antagonist scopolamine (10 mM) or the M 4 -selective toxin mamba toxin 3 (MT3; 1 mM) induced an increase in mIPSC frequency (Table S1 ; Wilcoxon signed-rank test, p < 0.01; Figures 4C-4E) . Conversely, application of 10 mM VU0467154 induced a modest decrease in mIPSC frequency (Table S1 ; Wilcoxon signed-rank test, p < 0.05; Figures 4C-4E ). When these (C) Summary of data represented in (A) and (B). Positive modulation corresponds to an increased mIPSC frequency and negative modulation corresponds to decreased mIPSC frequency as compared to baseline. See also Figure S4 . Data are mean ± SEM with n = 8-10 per group. NS, not statistically significant by one-way ANOVA followed by Tukey's post hoc test.
(legend on next page) agents are applied to slices from D 1 -M 4 KO mice, their effect is absent or greatly reduced (Table S1 ; Figures 4C-4E; one-way ANOVA with Tukey's post hoc test, p < 0.001).
To directly determine whether release of ACh from the PPN onto M 4 receptors induces a tonic inhibition of D 1 -SPNs, we utilized a cre-dependent, constitutively active caspase 3 virus injected into the hindbrain of ChAT-Cre-positive animals (Yang et al., 2013) . Injection of the virus greatly reduced cholinergic cells in the hindbrain ( Figure 4F ). In ex vivo recordings from slices prepared from caspase3 or control virus-injected ChAT-Cre mice, GABAergic cells of the SNr from cholinergic depleted animals had a higher baseline mIPSC frequency than control virus-injected ChAT-Cre animals (Figures 4F-4H ; Table S1 ; MannWhitney test, p < 0.05) and were no longer responsive to MT3 ( Figure 4G ). Taken together, these data suggest that there is a high basal activity of M 4 and that cholinergic projections from the hindbrain exert an M 4 -mediated inhibition of transmission at GABAergic terminals from D 1 -SPNs. D 1 and M 4 Converge on AC to Alter mIPSC Frequency D 1 couples to Ga olf , which activates AC in D 1 -SPNs, in a manner similar to Ga s in other cell types (Zhuang et al., 2000) . Thus, it is possible that D 1 increases mIPSCs through a cAMP-dependent mechanism and that M 4 inhibits D 1 responses by Ga i/o -mediated inhibition of AC and production of cAMP. We first perfused SNr slices with 50 mM of the AC activator forskolin (FSK) to increase intracellular cAMP levels. In both WT and D 1 -M 4 KO animals, bath application of FSK resulted in a significant increase in mIPSC frequency ( Figure S5 ; Wilcoxon signed-rank test, p < 0.05). Additionally, 10 mM Oxo-M, 10 mM VU0467154, or a combination of subthreshold concentrations of Oxo-M and VU0467154 blocked FSK-induced increases in mIPSC frequency (Figures S5A and S5B ; one-way ANOVA with Tukey's post hoc test, p < 0.01), but not D 1 -M 4 KO animals ( Figures  S5C and S5D ; one-way ANOVA with Tukey's post hoc test, p > 0.05).
To further test the hypothesis that the effects of M 4 on D 1 are mediated by reciprocal effects on AC activity, we utilized a b2-Opto-XR optogenetic construct injected into the striatum. This construct activates AC and accumulation of cAMP (Siuda et al., 2015) . Since D 1 -SPNs, but not SPNs of indirect pathway, project to the SNr, our coronal sectioning technique provided sections in which the construct is only expressed in D 1 -SPN terminals in the SNr (Figures 5A and 5B ). Activation of AC by optical stimulation in SNr increased mIPSC frequency in both WT and D 1 -M 4 KO animals (Table S1 ; Figures 5C-5F ; Wilcoxon signedrank test, p < 0.001). Also, consistent with our other studies, the increase in mIPSC frequency due to b2-Opto-XR stimulation could be blocked with 10 mM Oxo-M or a combination of 2 mM Oxo-M and 5 mM VU0467154 in WT (Table S1 (Foster et al., 2016) and reduce amphetamine-induced increases in extracellular DA concentrations . Furthermore, fMRI studies showed that M 4 PAMs inhibit effects of amphetamine using cerebral blood volume (CBV) measurements in striatum and other forebrain structures . CBV fMRI is an indirect hemodynamic measure of neural activity. If M 4 PAMs inhibit D 1 signaling in the SNr by direct actions on D 1 /cAMP signaling in D 1 -SPNs, M 4 PAMs should inhibit effects of direct-acting D 1 agonists on CBV in this region. Injection of a behaviorally active dose of SKF82958 (1 mg/kg, i.p.) induced significant increases in CBV compared to baseline across the SNr and striatum, as well as in the motor cortex (Figures 6A-6D ; Mann-Whitney test, p < 0.001 for each area). Interestingly, pre-treatment of rats with VU0467154 (30 mg/kg, i.p.) induced a significant reversal of SKF82958-induced increases in D 1 activation in the SNr, as well as the motor cortex, which is downstream of the SNr in the BG motor circuit ( Figures 6A,  6B , and 6D; Mann-Whitney test, p < 0.0001 for each area). These (F) Summary of data represented in (E). Positive modulation corresponds to an increased mIPSC frequency and negative modulation corresponds to decreased mIPSC frequency as compared to baseline. See also Figure S5 . Data are mean ± SEM with n = 8-10 per group (C and D) and n = 8-14 per group (E and F). *p < 0.05, **p < 0.01, ***p < 0.001; NS, not statistically significant by one-way ANOVA followed by Tukey's post hoc test. data are consistent with the hypothesis that M 4 activation inhibits D 1 signaling at the level of the SNr. Interestingly, in contrast to its effects on amphetamine-induced increases in CBV in the striatum , the M 4 PAM did not reverse the response to the D 1 agonist in the striatum (Figures 6A and 6C ; Mann-Whitney test, p > 0.05). The finding that the M 4 PAM only reversed SKF82958-induced CBV responses in the SNr and motor cortex, but not the striatum, suggests that the M 4 PAM directly inhibits D 1 signaling in the SNr. Additionally, these data, combined with the previously reported ability of M 4 PAMs to inhibit striatal DA release and block CBV responses to amphetamine, suggest that M 4 PAM activity in the striatum may be more important in inhibiting responses to DA release Foster et al., 2016) .
Interestingly, the M 4 PAM did not inhibit the CBV response to the D 1 agonist in regions that are not involved in regulation of motor function, including the sensory and cingulate cortices, or hippocampus (Figures 6A and 6E ; Mann-Whitney test, p > 0.05). In contrast to its actions in the SNr, VU0467154 enhanced SKF82958-evoked changes in CBV in the hippocampus (Figures 6A and 6F ; Wilcoxon-Mann-Whitney U test, p < 0.01) and induced a significant increase in the rise time of D 1 activation in the cingulate cortex as indicated by a faster rate of increase in CBV ( Figure S6 ; Mann-Whitney test, p < 0.01). Additionally, we tested the effects of M 4 PAM administration alone to determine if we could detect baseline changes in CBV induced by the M 4 PAM, but did not observe any changes in any brain area examined ( Figure S7 ; Mann-Whitney test, p > 0.05). This suggests that anesthesia during fMRI may diminish brain responses and our signal-to-noise window to detect changes in BG output.
Local D 1 Activation in the SNr Is Sufficient to Increase Locomotor Activity, and This Effect Is Blocked by mAChR Agonists
The present study raises the possibility that cholinergic projections and M 4 in the SNr may play a major role in regulating motor activity. To test this hypothesis, we performed a series of microinjection experiments to inject mAChR agonists or antagonists into the SNr. Fifteen minutes prior to microinjection, 3 mg/kg of the M 1 antagonist VU0255035 (i.p.) was given to block M 1 receptor activation (Xiang et al., 2012) . We then unilaterally injected 1 mL of 0.5 mg/mL of Oxo-M or vehicle (sterile water) into the SNr. Oxo-M, but not vehicle, induced ipsilateral turning within the first 15 min after microinjection ( Figure 7A ; Mann-Whitney test, p < 0.01). Additionally, when the direct pathway was activated through systemic administration of 0.3 mg/kg SKF82958, microinjection of Oxo-M into the SNr produced rotations significantly different than baseline and not significantly different than the Oxo-M microinjection alone group ( Figure 7A ; Kruskal-Wallis test, p < 0.05). Microinjection of Oxo-M into the SNr of D 1 -M 4 KO mice produces significantly fewer rotations than in littermate controls ( Figure 7B ; Mann-Whitney test, p < 0.05), suggesting that activation of M 4 expressed on D 1 -SPN terminals in the SNr is sufficient to block locomotor activity.
Additionally, we microinjected 1 mL of 3 mg/mL scopolamine bi-laterally into the SNr to determine if antagonizing M 4 receptors in the SNr could alter locomotor activity. Consistent with our hypothesis, microinjection of scopolamine into the SNr increased locomotor activity of WT animals compared to vehicle ( Figure 7C ; one-way ANOVA with Tukey's post hoc test, p < 0.05), but this effect was absent in D 1 -M 4 KO mice ( Figure 7C ; one-way ANOVA with Tukey's post hoc test, p > 0.05). While the volume of the microinjection likely caused spillover of scopolamine or Oxo-M into nearby brain regions, the absence of effect in D 1 -M 4 KO animals suggests that the effect is mediated by M 4 in D 1 -expressing SPNs. This provides in vivo evidence that inhibition of activity exerted by M 4 receptors on D 1 -SPNs at the level of the SNr diminishes motor activity and removal of this inhibition increases locomotor activity.
DISCUSSION
The striatum is critically involved in multiple brain functions and is highly regulated by DA and ACh. DA inputs from the SNc regulate two separate populations of SPNs that give rise to the direct and indirect pathway projections (Albin et al., 1989; Alexander et al., 1990; Beaulieu and Gainetdinov, 2011) . D 1 -SPNs send inhibitory projections to the major output nuclei of the BG, including the SNr. Indirect pathway SPNs express D 2 DA receptors (D 2 -SPNs) and have excitatory effects on SNr neurons by disinhibiting their major excitatory input (Albin et al., 1989; Beaulieu and Gainetdinov, 2011; Gerfen et al., 1990) . The locomotor-stimulating effects of DA are primarily mediated by activation of D 1 and D 1 -SPN projections to the SNr (Cabib et al., 1991; Wachtel et al., 1989) . While activation of cholinergic pathways can have multiple effects on striatal function, a major role of mAChRs is to inhibit DA signaling and oppose D 1 -mediated increases in locomotor activity (Foster et al., 2014 (Foster et al., , 2016 Gomeza et al., 1999 Gomeza et al., , 2001 ). This effect is thought to be mediated by release of ACh from ChIs projecting locally within the striatum (Aosaki et al., 1995 (Aosaki et al., , 2010 Bolam et al., 1984; Bonsi et al., 2011; Hersch et al., 1994; Wilson et al., 1990) .
While most studies of cholinergic modulation of BG function have focused on ChIs in the striatum, recent studies suggest that cholinergic neurons of the PPN also project to the striatum and SNr (Beninato and Spencer, 1987; Butcher and Hodge, 1976; Saper and Loewy, 1982) . The present study presents exciting new evidence that cholinergic projections from the PPN to the SNr activate M 4 in D 1 -SPN terminals to directly inhibit D 1 signaling. This M 4 -mediated response has a strong inhibitory influence on D 1 -mediated increases in transmission at D 1 -SPN synapses. The role of D 1 activation in increasing locomotor activity is well established (Beaulieu and Gainetdinov, 2011; Gerfen et al., 1990) . The present study suggests that, in addition to striatal ChI activity, selective activation of M 4 in the SNr can strongly inhibit D 1 activation of D 1 -SPN output and suppress related increases in locomotor activity.
Our studies are especially interesting in light of recent work demonstrating that optogenetic stimulation of cholinergic terminals from the PPN to DA neurons in the SNc induces depolarization of SNc DA neurons and increases locomotor activity (Xiao et al., 2016) . Also, we recently reported that postsynaptic activation of mAChRs can depolarize SNr projection neurons (Xiang et al., 2012) . Thus, PPN cholinergic projections are likely to have multiple actions on midbrain nuclei of the BG that are mediated by different ACh receptors and can have distinct actions to influence locomotor activity. This finding is directly analogous to the complex roles of ChIs on SPNs in the striatum, where selective M 4 activation reverses locomotor-stimulating effects of dopaminergic activation by inhibiting DA release (Foster et al., 2016) , inhibiting D 1 responses in D 1 -SPN cell bodies (Sá nchezLemus and Arias- Montañ o, 2006; Shen et al., 2015) , inhibiting excitatory transmission, and promoting induction of long-term depression in D 1 -SPNs (Pancani et al., 2015; Shen et al., 2015) . However, activation of ChIs also induces depolarization of both D 1 -SPNs and D 2 -SPNs through activation of nAChRs (Benarroch, 2012) and M 1 (Xiang et al., 2012) . Identifying individual ACh receptor subtypes involved in specific behaviors provides the opportunity to selectively modulate striatal function using receptor subtype-selective ligands.
The present findings are especially exciting in that they reveal that M 4 plays a powerful role in reducing DA signaling and regulation of locomotor activity at the level of the striatum and in D 1 -SPN terminals in the SNr. Thus, one important implication of this study is the possibility that M 4 -selective ligands may prove useful as novel therapeutic agents for treatment of disorders that involve dysregulation of dopaminergic signaling in the BG. Interestingly, mAChR antagonists were the first available treatments for Parkinson's disease (Unna and Vernier, 1956) , and clinical studies demonstrate significant improvement in multiple aspects of motor function in patients receiving mAChR antagonists (Jankovic et al., 2007; Katzenschlager et al., 2003) . However, non-selective mAChR antagonists have dose-limiting adverse effects that are likely mediated by blockade of M 1 , M 2 , and M 3 mAChRs (Drachman, 1977; Lang and Blair, 1989) . The current study suggests that more robust efficacy and fewer adverse effects may be achieved with highly selective M 4 antagonists. Additionally, our data indicate that M 4 induces a tonic inhibition of D 1 -SPNs that is normally opposed by D 1 activity. This suggests that in DA-depleted states, tonic M 4 -mediated inhibition of D 1 -SPN activity is likely to predominate, and that this inhibition could be relieved by selective M 4 antagonists.
In addition to the potential clinical utility of M 4 -selective antagonists, M 4 PAMs could be developed as treatments for disorders with excessive DA transmission. Consistent with this, M 4 PAMs have robust efficacy in multiple animal models of psychosis Foster et al., 2016) , HD (Pancani et al., 2015) , addictive disorders (Dencker et al., 2012) , and L-DOPAinduced dyskinesia (Shen et al., 2015) . Importantly, selective actions of M 4 PAMs on DA transmission in the BG could provide a major advantage to the use of DA receptor antagonists, a mainstay for treatment of schizophrenia. While blockade of DA receptors in the BG can provide therapeutic benefits, blockade of DA receptors in the hippocampus and cortical regions can impair cognitive function (Lynch, 1992; Tsang et al., 2015; Yohn et al., 2015) . Interestingly, our fMRI studies suggest that M 4 PAMs reduce CBV responses to D 1 agonists in the SNr and downstream motor cortex, but have no effect on responses to D 1 activation in cingulate cortex, hippocampus, and sensory cortex. In fact, the M 4 PAM enhanced responses to the D 1 agonist in hippocampus, and at early time points in the cingulate cortex. Based on this observation, and the mechanism by which M 4 PAMs locally inhibit DA release in the striatum (Foster et al., 2016) , it is possible that M 4 PAMs can selectively reduce DA signaling in the BG without cognition-impairing or other adverse side effects of DA receptor antagonists. In agreement with this notion, recent studies suggest that M 4 PAMs enhance, rather than inhibit, hippocampal and cortical-dependent forms of cognitive function Grannan et al., 2014) .
Taken together, our data support an expanded model of how DA and ACh can regulate D 1 -SPNs (summarized in Figure 8) , and suggest that regulation of D 1 -SPN terminals in the SNr may play a more important role in regulating activity through the direct pathway than previously appreciated. Further understanding and testing the implications of this expanded model in terms of diseases of the BG is an exciting avenue for further investigation and may yield additional understanding of the circuitry of the BG, as well as open further novel therapeutic possibilities. Additionally, our data provide critical pre-clinical rationale and further understanding of the mechanistic underpinnings of the potential utility of M 4 antagonists or negative allosteric modulators for the treatment of movement disorders and M 4 PAMs for treatment of disorders that involve excessive DA transmission in the BG.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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METHOD DETAILS
Locomotor Testing Locomotor activity was tested in wild-type and D 1 -M 4 KO mice, 8-12 weeks old, using an open field system (OFA-510, MedAssociates, St. Albans, VT) with three 16 3 16 arrays of infrared photobeams. SKF82958-induced locomotor activity was assessed with the following paradigm: animals were habituated for 90 min in the open field before being injected with vehicle (10% tween-80 intraperitoneal (i.p.)) or VU0467154 (3, 10 or 30 mg/kg i.p., 10% tween-80 i.p.); 30 min later, vehicle (sterile water s.c.) or SKF82958 (1.0 mg/kg in sterile water subcutaneous (s.c.)) were administered, and locomotor activity was recorded for an additional 60 min (180 minute total session length). Data were analyzed using the activity software package (MedAssociates, St. Albans VT) and expressed as total beam breaks per 5 min bin.
Immunohistochemistry D 1 -td-Tomato mice were terminally anesthetized with an i.p. injection of ketamine (100 mg/kg) and xylazine (20mg/kg) cocktail and transcardially perfused with 0.1M PBS with 10 U/ml heparin and 2g/L glucose followed by ice-cold 4% paraformaldehyde (PFA) made in 0.1M PBS. Brains were dissected and postfixed at 4 C for 2 hours in 4% PFA, and then transferred to 30% sucrose in PBS at 4 C for cryopreservation. Once brains were saturated in sucrose, they were flash-frozen in a À55 C 2-methylbutane dryice bath and stored at À80 C until sectioning. Brains were sectioned at 40 mm on a sledge microtome (Leica, Deerfield, IL). After sectioning, brain slices were stored at À20 C in 50% glycerol in 0.1M PBS. Sections were rinsed three times with PBS. Sections were blocked by incubating sections for 1 hour in 5% normal donkey serum 5% normal horse serum containing 0.1% Triton X-100 in PBS at 4 C with agitation. After initial blocking, sections were stained using the mouse-on-mouse (M.o.M) primary antibody kit (Vector Labs, Berlingame, CA) modified for use with fluorescent secondary. Following three rinses in PBS, sections were incubated in M.o.M mouse IgG blocking buffer for 1 hour at room temperature, then washed 2 times in PBS. Sections were then incubated in M.o.M kit diluent and sections were then transferred to 1:100 mouse anti-M4 (Levey et al., 1991) in kit diluent for 24 hours at 4 C. After incubation in primary antibodies, sections were washed three times in PBS. Sections were then incubated in secondary antibodies diluted in kit diluent with 1:500 donkey anti mouse IgG conjugated with Alexa-647(Jackson Immuno-Research, West Grove, PA) for 2 hours at room temperature, and then washed 3 times in PBS. Sections were then mounted to positively charged glass slides (Thermo Fisher, New York, NY), air-dryed, and mounted in pro-long gold mounting media (Life Technologies, Grand Island, NY). Slides were imaged on a Zeiss LSM 510 inverted confocal. During imaging, Alexa-647 was false colored to green in order to aid in visualization of co-localization of signal with td-tomato.
coil. High-resolution fast spin-echo (fse) structural images were collected (repetition time [TR] 2550 ms; effective echo time [TEeff] 40 ms; number of excitations [NEX] 2; 128 3 128 matrix; 35 3 35 mm2 field of view; 14 contiguous slices, 1.0 mm thick). Pre-contrast reference images and post-contrast functional images were acquired (fse: TR 2600 ms; TEeff 36 ms; NEX 2; 64 3 64 matrix). To measure cerebral CBV, Molday iron oxide nanoparticles (MION, 30 nm; 20 mg/kg, i.v.; BioPAL, Worcester, MA) were injected and allowed to equilibrate. A 5-minute baseline was collected, then all subjects were administered vehicle or 30 mg/kg VU0467154 (i.p.) After 30 min, all rats were administered SKF89258 during the continuous data acquisition.
PhMRI data were processed using in-house MATLAB code (MathWorks, Natick, MA) and Analysis of Functional NeuroImages (AFNI; https://afni.nimh.nih.gov/). All brain-masked, motion-corrected (AFNI 2dreg) images were coregistered to the template anatomical images in AFNI. Fractional CBV changes were calculated on a voxel-wise basis for each subject using the equation: DCBV(t)/CBVo = [ln S(t) -ln So]/ [ln So -ln Spre], where S(t) is the measured signal at time t, So is the post-contrast baseline signal, and Spre is the pre-contrast baseline. Regions of interest (ROIs), pre-defined on the template, based on a rat brain atlas (Paxinos and Watson, 2007) , were applied to all coregistered subjects. Mean CBV changes (left and right hemispheres averaged) were calculated for each region of interest. Mean CBV changes were groups were compared between the two treatment groups using the Mann Whitney test in GraphPad Prism V5.04 (GraphPad Software, La Jolla, CA).
Rotation Behavioral Assay
After cannula implantation as described above, mice were allowed to recover, singly housed for 1 week. 15 minutes prior to the testing session, animals were given 3 mg/kg in 10% Tween-80 of the M 1 antagonist VU0255035 to prevent seizure-like activity. Vehicle (10% Tween 80) or 0.3 mg/kg SKF89258 i.p were also injected 15 minutes prior to microinjection. A 30 gauge needle was then placed through the guide cannula and 1 mL of 0.5 mg/mL Oxo-M or 1 mL of sterile water was microinjected into the SNr. Mice were placed into a cylinder and recorded for 15 min. A reviewer blinded to experimental conditions then scored the videos for total contralateral rotations.
Bilateral Microinjection Assay
After bi-lateral cannula implantation as described above, mice were allowed to recover, singly housed for 1 week. WT littermates or D 1 -M 4 KO animals were placed in an open field system (OFA-510, MedAssociates, St. Albans, VT) with three 16 3 16 arrays of infrared photobeams for 90 min to habituate before being bi-laterally microinjected with 1 mL vehicle (sterile water) or scopolamine (3mg/ml); and locomotor activity was recorded for an additional 60 min. Data were analyzed using the activity software package (MedAssociates, St. Albans VT) and for the 60 minutes following microinjection expressed as total distance traveled.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed in GraphPad Prism 5 (GraphPad, San Diego, CA). Various statistical tests were used throughout the paper with the following rationale: If the data were normally distributed as determined by a D'Agonstino and Pearson omnibus normality test, a t test (one or two tailed, or comparing to a hypothetical mean) was used for tests comparing 2 conditions. A one way ANOVA was utilized with either a Tukey's or Dunnett's post hoc comparison were used for data that had 3 or more conditions. If the data were not normally distributed a Wilcoxon matched pairs and rank test was used if there were two conditions and Kruksal-Wallis test with Dunnett's post comparison was used. All data in this paper are represented as mean with standard error of the mean. N, which represents individual animals in behavioral tests and individual cells in electrophysiology experiments, can be found in each figure legend.
